N/A
Manufactured by CVS
123 FDA adverse event reports analyzed
Last updated: 2026-04-15
AVOBENZONE, HOMOSALATE, OCTOCRYLENE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by CVS. The most commonly reported adverse reactions for AVOBENZONE, HOMOSALATE, OCTOCRYLENE include HEADACHE, MALAISE, DYSPNOEA, INSOMNIA, ASTHENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for AVOBENZONE, HOMOSALATE, OCTOCRYLENE.
Out of 29 classified reports for AVOBENZONE, HOMOSALATE, OCTOCRYLENE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 123 FDA FAERS reports that mention AVOBENZONE, HOMOSALATE, OCTOCRYLENE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include HEADACHE, MALAISE, DYSPNOEA, INSOMNIA, ASTHENIA, COVID-19. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list CVS in connection with AVOBENZONE, HOMOSALATE, OCTOCRYLENE. Always verify the specific product and NDC with your pharmacist.